go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

McNeil Healthcare (Ireland) Ltd

McNeil Healthcare (Ireland) Ltd
Airton Road, Tallaght, Dublin 24, Ireland
Telephone: +353 1 466 5200
Fax: +353 1 466 5316
Summary of Product Characteristics last updated on medicines.ie: 02/04/2012
SPC Non-Drowsy Sudafed Decongestant Syrup

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 02/04/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 5.1 - Pharmacodynamic properties
Date of revision of text on the SPC:   29-Mar-2012
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company



Section 4.3: “listed in Section 6.1” was added at the end of the proposed contraindication regarding excipients

Section 4.7: text changed to read Sudafed Decongestant Syrup has a negligible influence on the ability to drive and use machines

Section 5.1: Addition of the Pharmacotherapeutic Group and the ATC Code

 

Updated on 22/07/2011 and displayed until 02/04/2012
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
Date of revision of text on the SPC:   29-Apr-2011
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Section 4.2 (Posology and Method of Administration)
Amended to read:
Oral
Adults and Children over 12 years:  10ml syrup every 4-6 hours, up to four times a day
Children 6-12 years:  5ml syrup every 4-6 hours, up to four times a day.  Maximum dose: 20ml.  Use only when simple measures have failed to provide adequate relief.  Use for more than five consecutive days is not recommended.
Use in the Elderly:  There have been no specific studies of Non-Drowsy SUDAFED Decongestant Syrup in the elderly. Experience has indicated that normal adult dosage is appropriate.
Hepatic Dysfunction:  Caution should be exercived when administering Non-Drowsy SUDAFED Decongestant Syrup to patients with severe hepatic impairment.
Renal Dysfunction:  Caution shoudl be exercised when administering Non-Drowsy SUDAFED Decongestant Syrup to patients with moderate to severe renal impairment.


Section 4.3 (Contraindications)
Added:
Non-Drowsy SUDAFED Decongestant Syrup is contraindicated in children under 6 years


Section 4.4 (Special Warnings and Precautions for Use)

Although pseudoephedrine has virtually no pressor effects in normotensive patients, Non-Drowsy SUDAFED Decongestant Syrup should be used with caution in patients taking antihypertensive agents, tricyclic antidepressants or other sympathomimetic agents (such as decongestants, appetite suppressants and amphetamine-like psychostimulants).  The effects of a single dose of Non-Drowsy SUDAFED Decongestant Syrup on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment.

 

As with other sympathomimetic agents, Non-Drowsy SUDAFED Decongestant Syrup should be used with caution in patients with hypertension, heart disease, diabetes, hyperthyroidism, elevated intraocular pressure and prostatic enlargement.

 

            There have been no specific studies of Non-Drowsy SUDAFED Decongestant Syrup in patients with hepatic and/or renal dysfunction.  Caution should be exercised when using the product in the presence of severe hepatic impairment or moderate to severe renal impairment.

 

            Patients with rare hereditary problems of fructose intolerance, glucose – galactose malabsorption or sucrase – isomaltase  insuffiency should not take this medicine.

 

            Not more than 4 doses should be given in any 24 hours. Do not exceed the stated dose.

           

            Do not take with any other cough and cold medicine.

           

            Consult a pharmacist or other healthcare professional before use in children aged 6 to 12 years.



Updated on 21/07/2011 and displayed until 22/07/2011
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
Date of revision of text on the SPC:   29-Apr-2011
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company



Section 4.2:

Removal of indication for use in children under 6 years of age.
Addition of maximum daily dose information
Addition of extra warnings:

Use only when simple measures have failed to provide adequate relief.

Use for more than 5 consecutive days is not recommended

Section 4.3

CI in children under 6.


Section 4.4

Children 2 to 6 years: Not more than 3 doses should be given in any 24 hours. 

changed to:

Children 6 to 12 years: Not more than 3 doses should be given in any 24 hours. 

 

Consult a pharmacist or other healthcare professional before use in children under 6 years.
changed to:

Consult a pharmacist or other healthcare professional before use in children under 12 years.

Updated on 23/02/2011 and displayed until 21/07/2011
Reasons for adding or updating:
  • Change to section 4.8 - Undesirable effects
Date of revision of text on the SPC:   17-Feb-2011
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Update to section 4.8 to include cardiovascular system effects in line with the company core data sheet.
Updated on 26/04/2010 and displayed until 23/02/2011
Reasons for adding or updating:
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   01-Jun-2009
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Correct SPC loaded as error noticed on current version.
Updated on 02/09/2009 and displayed until 26/04/2010
Reasons for adding or updating:
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 1 - Name of medicinal product
  • Change to section 6.1 - List of excipients
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   30-Jun-2009
Legal Category:   Supply through pharmacy only

Free-text change information supplied by the pharmaceutical company

Renewal Change have been implemented:

Change to mname from elixir to syrup.
Inclusion of excipients above the threshold.
Inclusion of E numbers where appropriate.
Revised renewal date
Updated on 07/10/2008 and displayed until 02/09/2009
Reasons for adding or updating:
  • Change to section 6.5 - Nature and contents of container
Date of revision of text on the SPC:   10/2008
Legal Category:   retail sale through pharmacy only

Free-text change information supplied by the pharmaceutical company

Change from "Plastic" to "HDPE"
Updated on 25/06/2008 and displayed until 07/10/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
Date of revision of text on the SPC:   06/2008
Legal Category:   retail sale through pharmacy only

Free-text change information supplied by the pharmaceutical company

Added to Section 4.4:
 
 

Not more than 4 doses should be given in any 24 hours. Do not exceed the stated dose.

Do not take with any other cough and cold medicine.

Consult a pharmacist or other healthcare professional before use in children under 6 years.
Updated on 11/03/2008 and displayed until 25/06/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing authorisation holder
Date of revision of text on the SPC:   01/2008
Legal Category:   retail sale through pharmacy only

Free-text change information supplied by the pharmaceutical company

To change the MAH from Pfizer Consumer Healthcare, Pottery Road, Dun Laoghaire, Co. Dublin to McNeil Healthcare (Ireland) Limited, Airton Road, Tallaght, Dublin 24, Ireland.

Updated on 03/11/2004 and displayed until 11/03/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for use
Updated on 19/08/2003 and displayed until 03/11/2004
Reasons for adding or updating:
  • New SPC for medicines.ie

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Pseudoephedrine Hydrochloride

Versions

 
02/04/2012 to Current
22/07/2011 to 02/04/2012
21/07/2011 to 22/07/2011
23/02/2011 to 21/07/2011
26/04/2010 to 23/02/2011
02/09/2009 to 26/04/2010
07/10/2008 to 02/09/2009
25/06/2008 to 07/10/2008
11/03/2008 to 25/06/2008
03/11/2004 to 11/03/2008
19/08/2003 to 03/11/2004
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo